8-K: Bausch + Lomb Announces Board Changes, Reaffirms 2026 Guidance

Bausch + Lomb Corporation announced updates to its Board of Directors and reaffirmed its full-year 2026 financial guidance, following a strong second quarter with 9% revenue growth.

Summary

• Bausch + Lomb Corporation has appointed four new directors to its Board: Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi, effective August 5, 2026.
• These appointments fill vacancies created by the resignations of Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr., and Andrew C. von Eschenbach, M.D., effective the same date.
• The new directors were appointed at the request of Bausch Health Companies Inc. (BHC), the controlling shareholder, which owns approximately 87% of the company's outstanding common shares.
• The company reported second-quarter revenue of $1.394 billion, an increase of 9% on a reported basis and 8% on a constant currency basis compared to Q2 2025.
• Net cash provided by operating activities increased significantly to $153 million in Q2 2026, up from $32 million in Q1 2026.
• Adjusted cash flow from operations (non-GAAP) more than tripled from $45 million in Q1 2026 to $161 million in Q2 2026.
• Bausch + Lomb is reaffirming its full-year 2026 guidance, with projected revenue between $5.440 billion and $5.540 billion, and Adjusted EBITDA (excluding Acquired IPR&D) between $1.025 billion and $1.075 billion.
• The company highlighted a diversified pipeline across various eye health areas and a focus on innovation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by strong Q2 financial performance and reaffirmed guidance, despite significant board changes.

Positives

• Second-quarter revenue increased by 9% on a reported basis and 8% on a constant currency basis, reaching $1.394 billion.
• Growth was broad-based across all segments, with double-digit revenue growth in Surgical and Pharmaceuticals.
• Significant margin expansion led to improved profitability in the second quarter.
• Net cash provided by operating activities increased substantially from $32 million in Q1 2026 to $153 million in Q2 2026.
• Adjusted cash flow from operations (non-GAAP) more than tripled from $45 million in Q1 2026 to $161 million in Q2 2026.
• Full-year 2026 revenue guidance of $5.440 billion to $5.540 billion is reaffirmed.
• Full-year 2026 Adjusted EBITDA (excluding Acquired IPR&D) guidance of $1.025 billion to $1.075 billion is reaffirmed.
• The company is advancing a diversified pipeline with innovations in dry eye disease, surgical technologies, consumer eye health, contact lenses, retinal diseases, and emerging areas.

Negatives

• Four directors resigned from the Board of Directors to facilitate the appointment of new directors.
• The new director appointments were made at the request of the controlling shareholder, Bausch Health Companies Inc., indicating continued significant influence from the parent company.
• Thomas W. Ross, Sr., one of the departing directors, will receive $400,000 for one year of consulting services.
• The company is paying prorated cash compensation and accelerating the vesting of restricted stock units for the departing directors.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, as discussed in its SEC and Canadian Securities Administrators filings.
• Guidance does not take into consideration potential changes in tariff policy due to its dynamic nature.
• The company may enter into additional business development transactions in the future, which could result in recurring Acquired IPR&D expenses.

Future Outlook

The company reaffirms its full-year 2026 guidance for revenue ($5.440 billion to $5.540 billion) and Adjusted EBITDA excluding Acquired IPR&D ($1.025 billion to $1.075 billion). The company also highlights its diversified pipeline and commitment to innovation to address structural trends in eye health.

Management Comments

• "We welcome our new directors and appreciate the service and contributions of those departing the Board," said Brent Saunders, chairman and CEO, Bausch + Lomb.
• "Over the past several years, we’ve been very transparent about our strategy and the work required to build a stronger Bausch + Lomb."
• "Today, we have exceptional talent across the company, momentum throughout our businesses and the strongest pipeline we’ve had in years."
• "Our second-quarter performance reflects what this team has methodically built and the disciplined execution behind it, and our focus remains on executing our strategy and delivering long-term value."

Industry Context

StockSavvy.ai notes that the changes in the Board of Directors, driven by the controlling shareholder, are a common occurrence in companies with significant majority ownership. The reaffirmation of guidance alongside strong Q2 results suggests operational stability and confidence in the company's strategic direction within the competitive global eye health market.

Management Changes

Corporate Governance

Legal Proceedings

• The resignations of the directors were not due to any disagreement or dispute with the Company.
• The company has agreed to pay prorated cash compensation and accelerate vesting of RSUs for departing directors as part of a general mutual release of certain claims.

Related Party Transactions

• Thomas J. Appio, newly appointed director, is the Chief Executive Officer of Bausch Health Companies Inc. (BHC), the controlling shareholder.
• Thomas W. Ross, Sr., a departing director, has entered into a consulting agreement with the Company for one year, for a fee of $400,000, payable quarterly.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and strong Q2 results are positive indicators. However, the influence of the controlling shareholder on board composition may be a point of consideration.
• Departing Directors: Will receive prorated compensation and accelerated vesting of RSUs, along with a consulting agreement for Mr. Ross.
• New Directors: Will receive standard compensation and indemnification as per company policy.
• Employees: Continued focus on strategy and innovation may provide stability and growth opportunities.

Next Steps

• The company will continue to execute its strategy and focus on delivering long-term value.
• The new directors will be considered for committee appointments and lead independent director roles.
• The Ross Agreement will be filed with the company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

Key Dates

Recommendation

The reaffirmation of guidance and strong Q2 financial performance are positive. However, the significant board changes initiated by the controlling shareholder, while not indicating immediate distress, warrant a 'hold' position to observe the integration of new directors and continued execution against the reaffirmed guidance.

Keywords

Board of Directors, Revenue Growth, Financial Guidance, Eye Health, Surgical, Pharmaceuticals, Cash Flow, Non-GAAP